Home/Pipeline/GLP-1 Receptor Agonist (Gan & Lee)

GLP-1 Receptor Agonist (Gan & Lee)

Type 2 Diabetes, Obesity

Clinical DevelopmentLicensed (Active)N/A

Key Facts

Indication

Type 2 Diabetes, Obesity

Phase

Clinical Development

Status

Licensed (Active)

Company

Lupin Limited

About Lupin Limited

Lupin Limited is a multinational pharmaceutical leader with a mission to catalyze treatments that transform hope into healing, driven by science and a patient-first mindset. The company has achieved global scale with operations in over 100 countries, 15+ manufacturing facilities, and a diversified business spanning generics, complex formulations, APIs, and emerging adjacencies in diagnostics and digital health. Its strategy integrates vertical integration, R&D in complex generics and biosimilars, and expansion into holistic healthcare solutions to drive sustainable growth in both developed and emerging markets.

View full company profile

Therapeutic Areas

Cardiovascular Diabetology Asthma/Respiratory Central Nervous System Gastrointestinal Anti-infectives Pain Management/NSAIDs

Other Type 2 Diabetes, Obesity Drugs

Drug	Company	Phase	Status
Generic Semaglutide (Oral)	Dr. Reddy's Laboratories	Development	Targeted launch FY27
Semaglutide Injection	Lupin	Market	Licensed for India
GLP-1 Agonist Program	Biolingus	Pre-clinical	Active
Semaglutide (Oral Generic)	Dr. Reddy's Laboratories	Pre-launch	Planned for FY27